Eiken Chemical Co., Ltd. · TSE:4549
Eiken Chemical — Q2 FY2011 Earnings Presentation
14 slides from Eiken Chemical's earnings presentation, Oct 27, 2010
Slide 1: Business performance briefing for the second quarter ending Mar. 2011
The business performance briefing for the second quarter ending Mar. 2011 EIKEN CHEMICAL CO., LTD. Oct. 27, 2010 Today's Contents 1. Consolidated operating results for the second quarter ending Mar. 2011 2. Primary strategies for the second quarter ending Mar. 2011 3. Primary strategies and consolid
Slide 2: Consolidated operating results for the second quarter ending Mar. 2011
Consolidated operating results for the second quarter ending Mar. 2011 EIKEN CHEMICAL CO., LTD. 2 Overview of business performance for the second quarter ending Mar. 2011 (Millions of yen) First half of the term ending Mar. 2011 YoY change Target value Actual results Ratio Difference Ratio Differenc
Slide 3: Sales by product category: fecal occult blood, immunological reagents
Sales by product category (Millions of yen) Term ended Mar. 2009 Term ended Mar. 2010 First half of the term Fecal occult blood 1st half Full year 1st half Full year ending Mar. 2011 diagnostic reagents (OC) 3,134 5,505 3,293 5,826 3,332 5,826 ●1.2% increase from the 5,505 corresponding term in the
Slide 4: Sales by product category: microbiological and dry chemistry reagents
Sales by product category (Millions of yen) Term ended Mar. 2009 Term ended Mar. 2010 First half of the term 1st half Full year 1st half Full year ending Mar. 2011 Microbiological reagents 2,287 4,472 2,271 4,449 2,298 4,472 4,449 ● 1.2% increase from the corresponding term in the previous year 2,28
Slide 5: Sales by product category: clinical chemistry and industry products
Sales by product category (Millions of yen) Term ended Mar. 2009 Term ended Mar. 2010 First half of the term 1st half Full year 1st half Full year ending Mar. 2011 Clinical chemistry reagents 496 934 455 864 418 934 ● 8.2% decrease from the 864 corresponding term in the previous year 496 455 418 ● D
Slide 6: Sales by product category: medical analyzers; overseas sales
Sales by product category (Millions of yen) Term ended Mar. 2009 Term ended Mar. 2010 First half of the term Medical analyzer, Full year Full year ending Mar. 2011 1st half 1st half molecular genetic-related 1,014 2,435 1,147 2,648 1,191 2,648 2,435 ● 3.8% increase from the corresponding term in the
Slide 7: Overseas sales by region; SG&A expenses and gross margin
Overseas sales (by region) U.S. Europe 665 576 697 559 268 287 234 281 275 Asia and other 201 region Term ended Mar. Term ended Mar. First half of the 2009 2010 term ending Mar. Term ended Mar. Term ended Mar. First half of the 2011 2009 2010 term ending Mar. 407 2011 263 209 128 139 Term ended Mar.
Slide 8: Balance sheets and cash flows
Balance sheets (Main Factor of Increase/Decrease) First half of the term ending (Millions of yen) Mar. 2011 Main reasons of Term ended Mar. 2010 increase/decrease Current liabilities ●Current assets Current liabilities 8,673 (-89) - Cash and bank deposits 162 8,763 - Notes and account receivable 728
Slide 9: Transition in R&D cost and investment in equipment
Transition in R&D cost and investment in equipment R&D cost (Millions of yen) Investment in (Millions of yen) Depreciation and (Millions of yen) equipment amortization (Target) 2,106 (Target) 2,032 1,924 1,086 886 922 859 (Budget) 690 713 1,018 927 915 532 438 444 422 398 295 Term ended Term ended T
Slide 10: Primary strategies: measures by country, R&D and new products
Primary strategies for the second quarter ending Mar. 2011 1. Measures in each country Japan ・ Promotion of ABC Examination mainly at checkup centers and facilities. ABC Examination: the examination for checking the health of the stomach ・Promotion of analyzer installation (Sales promotion of OC, Ur
Slide 11: FIND business (tuberculosis test); return to shareholders
Primary strategies for the second quarter ending Mar. 2011 3. FIND business (tuberculosis test) (1) In Japan ・ Applying for the approval of manufacturing and selling (2) Outside Japan ・ Start of the evaluation study in 4 countries - Started in Vietnam, Peru, South Africa, and Brazil. Already finishe
Slide 12: Primary strategies for the term ending Mar. 2011: global expansion
Primary strategies and consolidated earnings forecast for the term ending Mar. 2011 EIKEN CHEMICAL CO., LTD. 22 Primary strategies for the term ending Mar. 2011 1. Global expansion The U.S. ・ Expand OC to large-scale centers (Kaiser and Labcorp) and veterans’ hospitals. ・ Enter the food product insp
Slide 13: FIND business plans and earnings forecast
Primary strategies for the term ending Mar. 2011 2. FIND business (1) Tuberculosis test [In Japan] ・Prepare for the release after the approval [Outside Japan] Jan. 2011 Demonstration Study to be started Nov. 2011 Strategic And Technical Advisory Group For Tuberculosis Meeting Procedures for receivin
Slide 14: Eiken Chemical Co., Ltd. notes
EIKEN CHEMICAL CO., LTD. We contribute to the health of people as a comprehensive maker of clinical diagnostic agents. http://www.eiken.co.jp Notes This document is not the disclosed reference for financial instruments and exchange. Its accuracy and integrity are not guaranteed. The estimates, etc.